Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 16
2001 19
2002 44
2003 49
2004 31
2005 39
2006 35
2007 43
2008 50
2009 45
2010 45
2011 43
2012 59
2013 48
2014 40
2015 29
2016 41
2017 33
2018 47
2019 53
2020 55
2021 77
2022 60
2023 51
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

953 results

Results by year

Filters applied: . Clear all
Page 1
Gemtuzumab Ozogamicin.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 32697461 Free Books & Documents. Review.
No information is available on the clinical use of gemtuzumab ozogamicin during breastfeeding. Because gemtuzumab is a large protein molecule with a molecular weight of about 152,000 Da the amount in milk is likely to be very low.[1] It is also likely to be p …
No information is available on the clinical use of gemtuzumab ozogamicin during breastfeeding. Because gemtuzumab is a …
Gemtuzumab Ozogamicin.
[No authors listed] [No authors listed] 2023 Nov 30. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Nov 30. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643757 Free Books & Documents. Review.
Gemtuzumab ozogamicin is a humanized monoclonal antibody conjugate that is used in the therapy of acute myelogenous leukemia. Gemtuzumab ozogamicin has been linked to transient serum enzyme elevations during therapy and not uncommon instances of acute …
Gemtuzumab ozogamicin is a humanized monoclonal antibody conjugate that is used in the therapy of acute myelogenous leukemia. …
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.
Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S. Lambert J, et al. Haematologica. 2019 Jan;104(1):113-119. doi: 10.3324/haematol.2018.188888. Epub 2018 Aug 3. Haematologica. 2019. PMID: 30076173 Free PMC article. Clinical Trial.
No differences in early death rate were observed between arms. The main toxicity associated with gemtuzumab ozogamicin was prolonged thrombocytopenia. Veno-occlusive disease (including after transplant) was observed in 6 patients in the gemtuzumab ozogamic …
No differences in early death rate were observed between arms. The main toxicity associated with gemtuzumab ozogamicin was pro …
Gemtuzumab Ozogamicin: Back Again.
Selby C, Yacko LR, Glode AE. Selby C, et al. J Adv Pract Oncol. 2019 Jan-Feb;10(1):68-82. Epub 2019 Jan 1. J Adv Pract Oncol. 2019. PMID: 31308990 Free PMC article. Review.
This regimen has undergone multiple modifications and patient performance status-based stratifications, but has remained the first-line therapy for AML for the past 45 years. In September 2017, gemtuzumab ozogamicin returned to market and shortly thereafter was adde …
This regimen has undergone multiple modifications and patient performance status-based stratifications, but has remained the first-line ther …
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, Récher C, Chilton L, Moorman AV, Burnett AK. Hills RK, et al. Lancet Oncol. 2014 Aug;15(9):986-96. doi: 10.1016/S1470-2045(14)70281-5. Epub 2014 Jul 6. Lancet Oncol. 2014. PMID: 25008258 Free PMC article. Review.
BACKGROUND: Gemtuzumab ozogamicin was the first example of antibody-directed chemotherapy in cancer, and was developed for acute myeloid leukaemia. ...These data suggest that the use of gemtuzumab ozogamicin should be reassessed and its licence status …
BACKGROUND: Gemtuzumab ozogamicin was the first example of antibody-directed chemotherapy in cancer, and was developed for acu …
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association. Castaigne S, et al. Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5. Lancet. 2012. PMID: 22482940 Clinical Trial.
FINDINGS: 280 patients were randomly assigned to the control (n=140) and gemtuzumab ozogamicin groups (n=140), and 139 patients were analysed in each group. ...The findings warrant reassessment of gemtuzumab ozogamicin as front-line therapy for acute m …
FINDINGS: 280 patients were randomly assigned to the control (n=140) and gemtuzumab ozogamicin groups (n=140), and 139 patient …
Gemtuzumab ozogamicin.
McGavin JK, Spencer CM. McGavin JK, et al. Drugs. 2001;61(9):1317-22; discussion 1323-4. doi: 10.2165/00003495-200161090-00007. Drugs. 2001. PMID: 11511025 Review.
Gemtuzumab ozogamicin is a humanised monoclonal IgG4 antibody, linked to a cytotoxic calicheamicin derivative. ...About one-third of 11 children and adolescents treated with 2 doses of 9 mg/m2 gemtuzumab ozogamicin in a phase I study showed <5% bone …
Gemtuzumab ozogamicin is a humanised monoclonal IgG4 antibody, linked to a cytotoxic calicheamicin derivative. ...About one-th …
Gemtuzumab ozogamicin in acute myeloid leukemia.
Godwin CD, Gale RP, Walter RB. Godwin CD, et al. Leukemia. 2017 Sep;31(9):1855-1868. doi: 10.1038/leu.2017.187. Epub 2017 Jun 13. Leukemia. 2017. PMID: 28607471 Review.
CD33 is variably expressed on leukemia blasts in almost all patients with acute myeloid leukemia (AML) and possibly leukemia stem cells in some. Efforts to target CD33 therapeutically have focused on gemtuzumab ozogamicin (GO; Mylotarg), an antibody-drug conjugate d …
CD33 is variably expressed on leukemia blasts in almost all patients with acute myeloid leukemia (AML) and possibly leukemia stem cells in s …
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
Gottardi M, Sperotto A, Ghelli Luserna Di Rorà A, Padella A, Cangini D, Giannini MB, Simonetti G, Martinelli G, Cerchione C. Gottardi M, et al. Minerva Med. 2020 Oct;111(5):395-410. doi: 10.23736/S0026-4806.20.07019-6. Epub 2020 Sep 21. Minerva Med. 2020. PMID: 32955828 Free article. Review.
On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin for treatment of relapsed or refractory CD33(+) acute myeloid leukemia. This signals a new chapter in the long and unusual story of gemtuzumab ozogamicin, which …
On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin for treatment of relapsed or refrac …
953 results

Searches related to "gemtuzumab ozogamicin"